Cavinton intravenously10mg-2ml №10

Use - Reduction of neurological and mental disorders associated with impaired cerebral blood supply, such as transient ischemic attack, ischemic stroke, symptomatic therapy of stroke consequences, vascular dementia, cerebral atherosclerosis, post-traumatic and hypertensive encephalopathy, vertebrobasilar insufficiency. - Thrombosis/occlusion of the central retinal artery or vein. How to take - The drug is intended for intravenous drip infusion. - It should be administered slowly; the infusion rate should not exceed 80 drops/min. - Intramuscular administration is prohibited. - Intravenous administration without prior dilution is prohibited. - For preparing the infusion, physiological saline solution or solutions containing dextrose (e.g., Salsol, Ringer, Rindex, Reomacrodex) can be used. - The infusion solution with Cavinton should be used within the first 3 hours after preparation. Contraindications - Acute stage of hemorrhagic stroke (for parenteral administration). - Severe ischemic heart disease (for parenteral administration). - Severe arrhythmias (for parenteral administration). - Pregnancy. - Lactation period (breastfeeding). - Hypersensitivity to vinpocetine or other components of the drug. - Presence of prolonged QT interval syndrome and concomitant use of drugs causing QT interval prolongation require periodic ECG monitoring. - Cavinton infusion solution contains sorbitol (160 mg/2 ml), therefore, in patients with diabetes mellitus, blood glucose levels should be monitored. - In case of fructose intolerance or 1,6-diphosphatase deficiency, the use of the drug should be avoided.